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Novelty and Impact:  Information on their individual risk of breast cancer can help women make decisions 
about breast cancer screening and prevention but current risk prediction models lack discriminatory accuracy. In 
this large prospective study, premenopausal women with AMH concentration in the top quartile had a 60% 
greater risk of breast cancer than women of the same age with AMH concentration in the bottom quartile.  
AMH is thus a candidate for inclusion in breast cancer risk prediction models for younger women.  
ABSTRACT 
A strong positive association has been observed between circulating anti-Müllerian hormone (AMH), a 
biomarker of ovarian reserve, and breast cancer risk in three prospective studies. Confirming this association is 
important because of the paucity of biomarkers of breast cancer risk in premenopausal women. We conducted a 
consortium study including ten prospective cohorts that had collected blood from premenopausal women. A 
nested case-control design was implemented within each cohort. A total of 2,835 invasive (80%) and in situ 
(20%) breast cancer cases were individually matched to controls (n = 3,122) on age at blood donation. AMH 
was measured using a high sensitivity enzyme-linked immunoabsorbent assay. Conditional logistic regression 
was applied to the aggregated dataset. There was a statistically significant trend of increasing breast cancer risk 
with increasing AMH concentration (ptrend across quartiles < 0.0001) after adjusting for breast cancer risk 
factors. The odds ratio (OR) for breast cancer in the top versus bottom quartile of AMH was 1.60 (95% CI = 
1.31-1.94). Though the test for interaction was not statistically significant (pinteraction =  0.15), the trend was 
statistically significant only for tumors positive for both estrogen receptor (ER) and progesterone receptor (PR): 
ER+/PR+: ORQ4-Q1 = 1.96, 95% CI = 1.46-2.64, ptrend <0.0001; ER+/PR-: ORQ4-Q1 = 0.82, 95% CI = 0.40-1.68, 
ptrend = 0.51; ER-/PR+: ORQ4-Q1 = 3.23, 95% CI =0.48-21.9, ptrend = 0.26; ER-/PR-: ORQ4-Q1 = 1.15, 95% CI = 
0.63-2.09, ptrend = 0.60. The association was observed for both pre- (ORQ4-Q1= 1.35, 95% CI= 1.05-1.73) and 
post-menopausal (ORQ4-Q1 =1.61, 95% CI = 1.03 - 2.53) breast cancer (pinteraction =  0.34). In this large consortium 
study, we confirmed that AMH is associated with breast cancer risk, with a 60% increase in risk for women in 
the top vs. bottom quartile of AMH.  
 Anti-Müllerian hormone (AMH) is produced in the ovaries by the granulosa cells of pre-antral and early antral 
follicles 1. Circulating AMH is present in females at birth, peaks around age 20-25, and becomes undetectable 
after menopause, when the ovarian follicle reserve is depleted 2. AMH concentration has been shown to reflect 
the size of the follicular pool 3 and is a strong predictor of age at menopause 4-6.  
The hypothesis that AMH plays a role in breast cancer development came from laboratory experiments 
that showed AMH stimulates apoptosis and reduces breast tumor growth 7-9, suggesting a protective role. On the 
other hand, the strong positive correlation of AMH with age at menopause suggests that women who have 
higher AMH could be at higher risk of breast cancer than women of the same age with lower AMH, because 
they are expected to reach menopause at a later age and thus have longer remaining duration of exposure to high 
concentrations of steroid sex hormones 10, 11.  
A small cross-sectional study reported an inverse association of AMH concentration with breast cancer 
12 and a case-control study found no association 13. However, AMH was measured at or after diagnosis, and 
might not reflect the AMH concentration before cancer development. In 2009, Dorgan et al. reported a strong 
positive association between AMH concentration and risk of breast cancer in a case-control study nested within 
the Columbia, Missouri Serum Bank 14. Subsequently, two other reports from prospective studies (the Sister 
Study 15 and the Nurses’ Health Studies (NHS and NHSII) 16) also reported a positive, though weaker, 
association. Confirming the AMH-risk association is important because of the paucity of biomarkers in 
premenopausal women: while sex hormones (estrogens and androgens) measured in postmenopausal women are 
strongly associated with breast cancer risk 17, they show only weak associations when measured in 
premenopausal women 18, 19. 
We report here on a collaborative study that had for objectives to confirm the AMH-breast cancer risk 
association in a large study and to examine this association in relevant subgroups (i.e., by invasiveness, tumor 
receptor status, menopausal status at diagnosis, and various baseline characteristics). Ten prospective cohorts 
participated, including the four cohorts that previously published on this topic.  
       
METHODS 
Study Design and Case and Control Selection 
The ten participating cohorts are: Breakthrough Generations Study (BGS); Campaign Against Cancer and Heart 
Disease (CLUE II); Columbia, Missouri Serum Bank (CSB); Guernsey cohort (Guernsey); Nurses’ Health 
Study (NHS); Nurses’ Health Study II (NHSII); Northern Sweden Mammography Screening Cohort (NSMSC); 
New York University Women’s Health Study (NYUWHS); Hormones and Diet in the Etiology of Breast 
Cancer (ORDET); and the Sister Study. These cohorts are briefly described in Table 1. Each cohort was 
approved by its institutional review board. 
 A nested case-control design was used. With the exception of the Sister Study, which joined this 
collaborative effort later 15, all cohorts used the same general selection procedures. Eligibility criteria for cases 
and controls were: 1) premenopausal women of any age (or age <50 years if menopausal status was unknown, 
for example due to hysterectomy) at blood donation; 2) no prior diagnosis of cancer (except non-melanoma skin 
cancer); 3) for women who had had a hysterectomy, no history of bilateral oophorectomy; and 4) no current or 
prior use of hormone therapy. Incident cases of invasive or in situ breast cancer were included. Within each 
cohort, one control was selected for each case using incidence density sampling; matching factors included age 
and date at blood donation (age-matching criteria for different cohorts ranged from age ±6 mo to ±2 yrs, except 
ORDET which matched on age ±3 yrs and CSB which used ±5 yrs). Only 162 (6%) had a difference in age ≥ 2 
years and only 30 case-control pairs (1%) had a difference in age ≥ 3 years. Some cohorts had additional 
matching criteria (appendix Table 1 14-16, 19-27). In the NHS and NHSII, cases diagnosed after menopause were 
not included 16. The differences in procedures for the Sister Study 15 were: 1) in addition to being 
premenopausal at blood donation, women had to be between the ages of 35 and 54; 2) two controls were 
selected for each case; and 3) women reporting use of hormone therapy were included in the initial study but are 
excluded from this report. 
Laboratory Assays  
With the exception of the Sister Study, AMH concentration was measured using a picoAMH enzyme-linked 
immunoabsorbent assay (Ansh Labs, Webster, TX). NYUWHS samples were measured at Massachusetts 
General Hospital (MGH) and samples from the other eight cohorts were subsequently measured at Ansh Labs 
due to the closure of the MGH laboratory. Each batch (up to 70 samples per batch) contained 2-4 blinded 
quality control samples. Samples from a case and her matched control(s) were assayed together in the same 
batch. The samples were labeled in such a way that the laboratory was blinded with respect to case/control or 
quality control status.  The overall cohort-specific coefficients of variation (CVs) were <10%, except for the 
NYUWHS (CV = 17%). The Sister Study samples were measured at the University of Southern California 
using an Ultrasensitive ELISA (Ansh Labs, Webster, TX), and samples below the lower limit of detection of 
this assay (0.5 pmol/l) were re-measured using the picoAMH ELISA. The inter-batch CVs in the Sister Study 
were 14.5% 15.  
We conducted a calibration study to examine how NYUWHS and Sister Study measurements compared 
to measurements performed at Ansh Labs, where the samples from the 8 other cohorts were analyzed. Excellent 
agreement (intraclass as well as Pearson correlations > 0.98, Appendix Figure 1) was found for both cohorts. 
Thus, we did not calibrate the AMH measurements. 
Testosterone had been measured previously for 70% of the matched sets using methods described in 15, 19, 
24, 25, 28-30 (see also Supplementary Methods). For the remaining 30% (all sets from CLUE II, NHS, and NSMSC 
plus a subset of sets from Guernsey, NYUWHS, and ORDET cohorts), testosterone was newly measured at the 
Mayo Clinic Endocrine Laboratory using LC-MS/MS. Intra- and inter-batch CVs were <7% and <9%, 
respectively. Previous testosterone measurements were calibrated to the Mayo Clinic LC-MS/MS assay (see 
Supplementary Methods). 
Covariate Data 
Each cohort sent individual data on breast cancer risk factors and factors possibly related to AMH concentration 
to NYU, where data harmonization was conducted. Data collected closest to blood draw were used. Data on 
subsequent age at menopause were also obtained (except for CSB and NSMSC which did not send follow-up 
questionnaires).   
Statistical Analysis 
Subjects whose AMH concentration was below the lowest detectable value (range <2%-18% depending on 
cohort, Table 3) were assigned the lowest detectable value (LDV) for their cohort (LDV differed by cohort due 
to different dilution factors) divided by . Samples with AMH above the highest detectable value (n=14) were 
set to the highest detectable value. AMH concentration was log2-transformed to normalize its distribution.  
 Conditional logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals 
(95% CIs) for the association of AMH with breast cancer risk. Our main analyses were based on cohort-specific 
quartiles, defined using the controls’ distribution. We also conducted analyses using consortium-wide quartiles. 
Restricted cubic splines were used to assess deviation from linearity 31. 
Because the number of cases in some cohorts was fairly small, which was a concern for subgroup 
analyses, our main analyses are based on the aggregated data, i.e. combining individual data from all cohorts. 
We also conducted an analysis using a two-stage approach, estimating ORs within each cohort prior to pooling 
using a random-effects model 32.   
Potential confounders included in the multivariate model were: race, education, BMI, age at menarche, 
parity, age at first full-term pregnancy (FTP), oral contraceptive use, partial/unilateral oophorectomy, family 
history of breast cancer, history of benign breast biopsy, and smoking. For all continuous variables, only a small 
proportion (< 3%) of data was missing and we used the cohort-specific median for imputation. For categorical 
variables with missing data, an ‘unknown’ category was created. We also conducted analyses adjusting for total 
testosterone (ordered cohort-specific quartiles) in addition to these factors.  
Stratified analyses were conducted to examine whether the AMH-breast cancer risk association varied 
according to participant or tumor characteristics. All tests for heterogeneity and effect modification were 
performed by comparing models with/without an interaction term between the covariate and ordered categorical 
AMH.  The Wald test was used to assess the statistical significance of the interactions. All tests for interaction 
used cohort-specific AMH quartiles (coded as ordered categories 1, 2, 3, 4) and each of the other variables as 
categorical variables with unordered levels (as shown in the tables). For analyses stratified by age-related 
covariates (age at blood draw, age at diagnosis/index date (for controls, the date of diagnosis of the matched 
case), and menopausal status at diagnosis/index date), we used AMH quartiles based on the controls’ 
distribution within each of four age-at-blood-draw categories (≤40, 41-44, 45-49, ≥50) within each cohort. The 
unconditional logistic regression model, adjusted for age at blood draw and cohort, gave results very similar to 
the conditional model; therefore, we used unconditional logistic regression, adjusting for age and cohort, in 
analyses stratified by characteristics which were not matching variables, in order to include the maximum 
number of subjects in the analysis.  
All analyses were conducted using SAS 9.4 (SAS Institute Inc., Cary, NC, USA).  All tests were two-
sided and were considered statistically significant if p < 0.05.  
RESULTS 
 A total of 2,835 breast cancer cases and 3,122 controls were included in the study. Participant characteristics 
are described in Table 2 for the whole consortium, and in Appendix Table 2 for each cohort. The majority of 
subjects (>65%) were between the ages of 40 and 49 at blood draw. Overall, the differences between cases and 
controls were as expected. Controls had a higher proportion of obese women than cases, as expected in 
premenopausal women. More cases than controls were nulliparous or had their first FTP after age 30. Cases 
were more likely to have a first-degree family history of breast cancer and a history of benign breast biopsy. 
The proportion of current users of oral contraceptives was small (cases: 6.2%, controls: 5.7%), reflecting the 
fact that this was an exclusion criterion in several cohorts. 
The AMH assay results are shown in Table 3. The geometric mean AMH for controls varied by cohort, 
with a >4-fold difference between the lowest and highest values (0.71 pmol/l in the NSMSC and 5.21 pmol/l in 
NHSII). Adjusting for age, which was strongly related to AMH (Spearman correlation coefficient = -0.67), 
reduced these differences (2.3-fold difference: 1.36 pmol/l in Guernsey to 3.15 pmol/l in NHSII), though they 
remained statistically significant. In all cohorts except Guernsey, the age-adjusted geometric mean for cases was 
higher than for controls.  
The ORs for breast cancer in relation to AMH quartiles are shown in Table 4. In univariate analysis, 
there was a statistically significant trend of increasing risk with increasing AMH concentration (ORQ4-Q1 = 1.64 
(95% CI= 1.35-1.98); ptrend < 0.0001). Results were similar after adjustment for potential confounders (ORQ4-Q1 
= 1.60, 95% CI= 1.31-1.94; ptrend < 0.0001). Further adjusting for testosterone did not substantially alter the 
ORs, nor did removing one cohort at a time (data not shown). The ORs remained statistically significant after 
simultaneously excluding the four cohorts that published previously (ORQ4-Q1= 1.38, 95% CI= 1.07-1.79). Odds 
ratios were not appreciably different in analyses using consortium-wide AMH quartiles (Appendix Table 3). 
The spline analysis showed no evidence of deviation from linearity (p = 0.13). Results were similar in the two-
stage analysis (multivariate-adjusted ORQ4-Q1  = 1.66, 95% CI= 1.30-2.12; Figure 1), which showed no evidence 
of heterogeneity by cohort (I2 = 22.7%, p = 0.23). 
Analyses stratified by tumor characteristics are shown in Table 5. We did not see evidence of 
heterogeneity by invasive/in situ status. While several assessments of joint receptor status have supported the 
idea that ER-/PR+ tumors occur infrequently 33-36, others did not find this joint receptor subtype to be 
reproducible 37-39. Because there has not yet been a resolution and we did not have the tumor tissues to re-assess 
receptor status with current IHC methods, we show analyses both by single and joint ER/PR receptor status. 
Although the interaction test was not statistically significant (pinteraction = 0.21), the association between AMH 
and risk was statistically significant for ER+ (ORQ4-Q1 = 1.74, 95% CI = 1.33-2.28; ptrend <0.0001) but not for 
ER- tumors (ORQ4-Q1 = 1.17, 95% CI = 0.68-2.01; ptrend = 0.54). Heterogeneity was observed for PR status 
(pinteraction = 0.02), with a statistically significant association for PR+ tumors (ORQ4-Q1 = 1.97, 95% CI = 1.48-
2.64; ptrend <0.0001) but no association for PR- tumors (ORQ4-Q1 = 1.00, 95% CI = 0.65-1.55; ptrend = 0.95). 
Though there was no statistically significant heterogeneity (pinteraction = 0.15) in the analysis by combined ER/PR 
status, the trend test was significant only for ER+/PR+. No statistically significant heterogeneity was observed 
between HER2+ and HER2- tumors (pinteraction = 0.37).  No association was seen for triple negative (ER-/PR-
/HER2-) tumors (ptrend = 0.95).  
No statistically significant heterogeneity of the AMH-risk association was found in analyses stratified by 
age at blood donation, age at diagnosis, or baseline characteristics (Appendix Tables 4 and 5), though the 
association appeared stronger among women ages ≥45 years at blood donation than for younger women.  
Table 6 shows the results by menopausal status at diagnosis/index date. No statistically significant 
heterogeneity was detected (pinteraction = 0.34). The OR comparing top vs. bottom AMH quartiles was 1.35 (95% 
CI= 1.05-1.73; ptrend = 0.03) for the premenopausal subgroup and 1.61 (95% CI= 1.03-2.53; ptrend = 0.03) for the 
postmenopausal subgroup. Further adjusting for subsequent age at menopause hardly altered the ORs in the 
postmenopausal subgroup.  
Stratified analyses were not appreciably different in analyses using consortium-wide quartiles (data not 
shown).   
DISCUSSION 
In this prospective study including 2,835 cases and 3,122 matched controls from ten cohorts, we found a 
positive association between circulating AMH concentration and breast cancer risk. Compared with women in 
the lowest AMH quartile, women in the top quartile had a 60% higher risk of breast cancer in analyses adjusting 
for potential confounders. The association appeared limited to ER+/PR+ tumors. It was observed for both 
premenopausal and postmenopausal breast cancer.  
Our study included six new cohorts in addition to the four that previously reported a positive association 
between AMH and breast cancer risk. Cases from these six cohorts represented 64% of the cases included in the 
study. Excluding one cohort at a time did not significantly alter the results and the association was still 
statistically significant when the four cohorts that published previously were simultaneously excluded (ORQ4-
Q1= 1.38, 95% CI= 1.07-1.79). Thus, and given the dose-response observed, we feel confident that our results 
are not due to random variation.  
 A statistically significant trend of increasing risk with increasing AMH was observed for ER+, PR+, and 
ER+/PR+ tumors. This suggests that estrogens and progesterone, whose binding to their respective receptors 
results in increased breast epithelial cell proliferation 11, 40, are involved in the mechanism underlying the AMH-
breast cancer association. AMH is not strongly correlated with estradiol (follicular r = 0.02; luteal r = 0.17; 
untimed r = 0.12) 14, 16, but is strongly predictive of age at menopause and is thus an indicator of remaining 
duration of exposure to the high levels of estrogens and progesterone observed prior to menopause. We also 
observed that ORs and dose-response trends were strongest for women who were ≥45 years of age at blood 
draw and thus approaching menopause. This suggests that AMH concentration during perimenopause may be 
particularly informative regarding breast cancer risk. Perimenopause is characterized by an increase in the 
number of anovulatory cycles, which lack the surge in progesterone observed in the luteal phase of ovulatory 
cycles, in addition to changes in patterns of estrogen concentrations. AMH concentration, as a marker of 
perimenopausal progression, would be expected to reflect ovarian sex hormone exposure during this life stage. 
These observations support the hypothesis that the AMH-breast cancer risk association may be explained, in 
part, by AMH acting as a marker of time to menopause. 
However, other observations from our study suggest that the association of AMH with risk is not 
explained entirely by its role as a marker of remaining years before menopause. First, we observed a positive 
association for premenopausal breast cancer. Also, the association of AMH with postmenopausal breast cancer 
was not attenuated by adjusting for age at menopause. We therefore cannot exclude an effect of AMH through 
other mechanisms, including a direct action of AMH, given the presence of AMH receptors in the breast 41.  
Because experimental studies have shown a protective effect of AMH against breast tumors related to 
basal-like histology, Nichols et al. hypothesized that AMH could protect against this tumor subtype 15. We did 
not observe a positive association with AMH for triple-negative tumors, a subgroup that substantially overlaps 
with the subgroup of basal-like tumors 42, 43. The number of cases in this subgroup, was small (115 cases) 
though, and additional studies specifically in the basal-like subgroup would be of interest.  
Besides its prospective design and large sample size, another strength of our study was that detailed data 
on breast cancer risk factors were available. Odds ratios were not much altered when we adjusted for these 
factors, suggesting that they do not confound the AMH-risk association. We also adjusted for testosterone, 
which has been consistently associated with risk of breast cancer in both pre- and post-menopausal women 19, 44. 
These two hormones were not correlated (age-adjusted Spearman correlation coefficient = 0.12) and ORs did 
not change substantially, suggesting that these two hormones act through different mechanisms. We used only 
one blood sample per participant, but AMH has been shown to vary little both within 45-47 and between 48, 49 
menstrual cycles and also for repeat measurements (intra-class correlation coefficients of 0.88 for measurements 
1 year apart, 0.67 for measurements taken 2-3 years apart, , and correlation of 0.66 for measurements taken 4 
years apart) 16, 50, 51. Further, using only one measurement in biomarker studies usually tends to attenuate true 
associations 52. Because neither biological/lifestyle variables (e.g. age, smoking, parity), nor the technical 
factors on which we had data (time in storage, type of sample (serum/plasma), time between collection and 
processing, and storage temperature) explained the differences in AMH concentrations we observed between 
cohorts, we do not know whether these differences reflect true differences between populations or technical 
artifacts. This is why we chose to conduct our analyses using cohort-specific quartiles, and our results should be 
interpreted on the relative scale (i.e. risk associated with levels in a specific quartile relative to women of the 
same age with levels in the lowest quartile) and not on the absolute scale (risk associated with absolute AMH 
concentration). 
We note some implications of our results. First, the protective effect of AMH against breast and 
gynecological cancers in laboratory studies has led to the suggestion that AMH could be used in the treatment 
of these cancers 53. Our results, however, indicate an opposite effect of AMH in women than observed in 
laboratory studies, which may be due to the use of supraphysiologic doses of recombinant AMH in those studies 
7, 9, 41, 54. The second implication regards breast cancer risk prediction models. Information on absolute risk is 
needed for younger women because guidelines regarding the age to start mammographic screening are not 
consistent 55-57 and because younger women tend to benefit most from preventive pharmacologic intervention 58. 
Current risk prediction models, though, have shown limited discriminatory accuracy 59. Our results suggest that 
AMH could improve breast cancer risk prediction models for younger women.  
In conclusion, we found that women with high AMH concentrations were at higher risk of breast cancer 
than women of the same age with lower AMH concentrations in a large prospective study. The association was 
statistically significant only for ER+/PR+ tumors, which suggests that the association is due, at least in part, to 
the role of AMH as an indicator of exposure to estrogens and progesterone. The association with 
postmenopausal breast cancer is also consistent with AMH reflecting remaining time to menopause; however, 
because this association was not attenuated with adjustment for age at menopause and because we also observed 
an association of AMH with pre-menopausal breast cancer, our results suggest that additional mechanisms are 
at play.   
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